| Serial Number | 87978084 |
| Word Mark | NAVICAN PRECISION CANCER CARE |
| Filing Date | Tuesday, May 30, 2017 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 4, 2019 |
| Registration Number | 5771248 |
| Registration Date | Tuesday, June 4, 2019 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, November 7, 2017 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| NOT AVAILABLE | "PRECISION CANCER CARE" |
| Goods and Services | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, June 6, 2017 |
| Primary Code | 042 |
| First Use Anywhere Date | Monday, April 23, 2018 |
| First Use In Commerce Date | Monday, April 23, 2018 |
| Party Name | IHC HEALTH SERVICES, INC. |
| Party Type | 31 - New Owner After Registration |
| Legal Entity Type | 54 - NOT AVAILABLE |
| Address | SALT LAKE CITY, UT 84111 |
| Party Name | Navican Genomics, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Party Name | Navican Genomics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Party Name | Navican Genomics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Event Date | Event Description |
| Friday, June 2, 2017 | NEW APPLICATION ENTERED |
| Tuesday, June 6, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, August 17, 2017 | ASSIGNED TO EXAMINER |
| Thursday, August 24, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, August 24, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, August 24, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, August 24, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Saturday, August 26, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Saturday, August 26, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Saturday, August 26, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Saturday, August 26, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, January 2, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Saturday, September 16, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sunday, October 1, 2017 | ASSIGNED TO LIE |
| Wednesday, October 18, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 7, 2017 | PUBLISHED FOR OPPOSITION |
| Tuesday, November 7, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Friday, June 29, 2018 | TEAS STATEMENT OF USE RECEIVED |
| Friday, June 29, 2018 | USE AMENDMENT FILED |
| Friday, June 29, 2018 | TEAS REQUEST TO DIVIDE RECEIVED |
| Friday, June 29, 2018 | DIVISIONAL REQUEST RECEIVED |
| Monday, July 16, 2018 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, July 16, 2018 | DIVISIONAL PROCESSING COMPLETE |
| Monday, July 16, 2018 | STATEMENT OF USE PROCESSING COMPLETE |
| Thursday, August 2, 2018 | NON-FINAL ACTION E-MAILED |
| Thursday, August 2, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, October 4, 2018 | SU - FINAL REFUSAL - WRITTEN |
| Thursday, August 2, 2018 | SU - NON-FINAL ACTION - WRITTEN |
| Thursday, September 13, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, September 13, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 14, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 4, 2018 | FINAL REFUSAL E-MAILED |
| Thursday, October 4, 2018 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, May 2, 2019 | SU-EXAMINER'S AMENDMENT WRITTEN |
| Thursday, May 2, 2019 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, May 2, 2019 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 2, 2019 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 2, 2019 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Friday, May 3, 2019 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Tuesday, June 4, 2019 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, August 14, 2019 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, June 4, 2024 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |